United Therapeutics Corp (UTHR) Easily Beats Q3 Views; Revs Top $200M
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $235.95 -0.44%
EPS Growth %: +19.1%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +19.1%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q3 EPS of $1.65, $0.92 better than the analyst estimate of $0.73. Revenue for the quarter came in at $201.7 million versus the consensus estimate of $194.77 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
